Corient Private Wealth’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $612K | Buy |
4,871
+671
| +16% | +$84.3K | ﹤0.01% | 1687 |
|
|
2025
Q1 | $465K | Sell |
4,200
-3,727
| -47% | -$412K | ﹤0.01% | 1632 |
|
|
2024
Q4 | $1.08M | Buy |
7,927
+3,094
| +64% | +$422K | ﹤0.01% | 1282 |
|
|
2024
Q3 | $557K | Buy |
4,833
+397
| +9% | +$45.7K | ﹤0.01% | 1651 |
|
|
2024
Q2 | $611K | Buy |
4,436
+617
| +16% | +$84.9K | ﹤0.01% | 1536 |
|
|
2024
Q1 | $527K | Buy |
3,819
+637
| +20% | +$87.9K | ﹤0.01% | 1598 |
|
|
2023
Q4 | $419K | Buy |
3,182
+23
| +0.7% | +$3.03K | ﹤0.01% | 1695 |
|
|
2023
Q3 | $355K | Buy |
3,159
+110
| +4% | +$12.4K | ﹤0.01% | 1657 |
|
|
2023
Q2 | $288K | Sell |
3,049
-2,145
| -41% | -$202K | ﹤0.01% | 1713 |
|
|
2023
Q1 | $526K | Buy |
+5,194
| New | +$526K | ﹤0.01% | 1353 |
|